SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Ambit Biosciences and Astellas Pharma Inc. Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology